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Background: The use of hepatic arterial therapy (HAT) with either yttrium-90 or drug-eluting bead
therapy for initially unresectable hepatic malignancies has risen significantly. The safety of hepatic
resection after hepatic arterial therapy (HAT) is not established.
Objective: The present study evaluates the safety profile for hepatic resection after HAT.
Methods: We identified 840 patients undergoing hepatectomy for primary or metastatic lesions. Forty
patients underwent HAT before hepatectomy (pre-HAT). A 1 : 4 case-matched analysis compared three
groups: (i) pre-HAT and pre-operative chemotherapy (n = 40); (ii) pre-operative chemotherapy (n = 160);
and (iii) no pre-operative therapy (n = 640). Controls were matched for age, resection type, maximal
tumour size and magnitude of resection. Morbidity and mortality among groups were compared using a
graded complication scale.
Results: There were no differences in post-operative complications, grade of complication or liver-
specific complications among the groups. A proportional hazards model for all patients did not demon-
strate any association between increased complications and either pre-HAT or pre-operative
chemotherapy when compared with patients without pre-operative therapy (P = 0.7).
Conclusions: Pre-HAT demonstrated similar morbidity, liver-specific morbidity and intra-operative com-
plications when compared with patients undergoing pre-operative chemotherapy alone or without pre-
operative chemotherapy. These results suggest that pre-HAT is safe and should not preclude
hepatectomy in carefully selected patients.
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Introduction
Primary and metastatic hepatic malignancies are common prob-
lems addressed by hepatobiliary surgeons and oncologists. Over
18 000 patients in the United States die from primary liver cancers
annually, and over half of the patients dying from aerodigestive
cancers will harbour hepatic metastases.1,2 In properly selected
patients, resection of both primary and metastatic hepatic malig-
nancies has been shown to extend survival.3 Unfortunately, many
patients will not be candidates for up-front resection because of
unfavourable anatomy, insufficient hepatic functional reserve or
aggressive tumour biology.
Recently, the use of hepatic arterial therapy (HAT) has emerged
as a useful treatment option for unresectable patients. HAT takes
advantage of the preferential hepatic arterial blood supply of
hepatic neoplasms to deliver cytotoxic therapies, while minimiz-
ing systemic toxicity.4 Two widely used HAT modalities include
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Yttrium-90 radioembolization and drug-eluting bead (DEB)
therapy, which employ hepatic arterial delivery of radioisotopes or
chemotherapy, respectively.
After HAT, a subset of initially unresectable patients will show a
favourable tumour response, allowing for consideration of hepatic
resection. Concerns over increased peri-hepatic inflammation
(potentially leading to difficult hepatic mobilization), as well as
the potential for hepatic parenchymal impairment (perhaps
leading to an increase in hepatic insufficiency after resection) have
left many surgeons reluctant to perform hepatectomy in this
group of patients. The aim of the present study was to examine the
safety of hepatectomy in patients who underwent pre-operative
hepatic arterial therapy (pre-HAT).
Materials and methods
Between November 2006 and August 2009, two prospectively col-
lected, institutional review board-approved databases were
reviewed. Analysis of a 460-patient, prospective, hepatic arterial
therapy registry and a 1642-patient prospective hepato-
pancreato-biliary database identified three groups of patients:
those who underwent HAT (yttrium-90 or DEB) before hepatec-
tomy (pre-HAT; n = 40), those who had pre-operative systemic
chemotherapy followed by resection (n = 160) and those who
underwent hepatectomy without pre-operative treatment
(n = 640).
All pre-HAT patients were included in the study. Comparison
groups were selected using 1 : 4 matching based on patient age,
disease distribution (number of lesions and maximal lesion diam-
eter), patient comorbidities (presence of cardiopulmonary disease
and hepatic dysfunction) and magnitude of hepatectomy. Major
hepatectomy was defined as3 Couinaud segments. Hepatic dys-
function was based upon patient histories, abnormal liver func-
tion tests or imaging suggestive of underlying hepatic pathology.
Before undergoing HAT, all patients underwent triple-phase
baseline computed tomography (CT) imaging. All HAT patients
were reviewed in a multidisciplinary conference, and determined
to be unresectable based on extent of disease, comorbidities and
disease histology. Contraindications to HAT included a contrain-
dication to angiographic and selective visceral catheterization;
non-patent portal vein; significant extrahepatic disease (>50% of
overall tumour burden); greater than 75% of hepatic parenchymal
tumour involvement; contraindication to doxorubicin or irinote-
can administration, pregnancy; severe liver dysfunction; and
severe cardiac comorbidities. Additionally, for patients undergo-
ing yttrium-90 radioembolization therapy, the presence of
significant hepatopulmonary shunting (>15%) constituted a con-
traindication to treatment.
Pre-HAT patients underwent treatment with either yttrium-90
radioembolization using SIR-Spheres (SIRTex Medical Ltd,
Sydney, Australia) or DEB therapy using the LC Bead (Biocom-
patibles UK, Ltd, Surrey, United Kingdom) loaded with either
doxorubicin or irinotecan. Methods for HAT delivery have been
previously reported.2,5,6
After HAT, the response to therapy was assessed using CT
imaging and characterized using modified response evaluation
criteria in solid tumours (RECIST) criteria.7 Follow-up CT
imaging was performed at 6 weeks to restage and confirm the
safety of these novel therapies. CT imaging was then obtained at 3
months post-treatment and thereafter at 3-month intervals to
determine treatment response. After each serial scan, the decision
on whether a particular patient required additional HAT treat-
ments, resection, observation or cessation of therapy was made at
a multidisciplinary conference with active input from surgeons,
medical oncologists, radiation oncologists, radiologists and
pathologists.
Patients were considered for resection after HAT based on
cross-sectional imaging showing a favourable response to HAT,
anatomic resectability of residual disease, absence of extrahepatic
disease, the patient’s functional status and a progression-free
interval of at least 9 months for atypical metastatic disease (i.e.
non-colorectal and non-neuroendocrine). Hepatic resections
were performed by the senior authors (R.C.G.M., C.R.S., K.M.M.)
and described based on Couinaud segments.8
Endpoints for this analysis were estimated blood loss (EBL),
requirement for post-operative transfusion, post-operative com-
plications, grade of complication, liver-specific complications and
90-day mortality. EBL was abstracted from the anaesthesia record.
The decision to transfuse packed red blood cells was made by the
operating surgeon based on clinical judgment for individual
patients. All post-operative complications were monitored for 90
days and graded prospectively according to a previously published
standard five-point scale.9 Briefly, Grade 1 complications required
only supportive care or oral medications; Grade 2 complications
required intravenous medication or parenteral nutrition; Grade 3
complications required intensive care unit admission or relatively
non-invasive procedures (e.g. esophagogastroduodenoscopy,
image-guided drainage); Grade 4 complications involved chronic
disability or required major reoperation (e.g. organ resection or
enteral diversion). Major complications were defined as Grade
3. Liver-specific complications were defined as complications
directly related to the liver parenchyma (i.e. biliary leakage, ascites
or hepatic insufficiency).
Resection specimens were submitted for routine pathologic
analysis. The non-tumour bearing liver was routinely assessed for
inflammation based on haematoxylin & eosin (H&E) staining.
Statistical analysis was performed with JMP® software, version
7 (SAS Inc., Cary, NC, USA). Groups were compared using analy-
sis of variance. P-values <0.05 were considered statistically signifi-
cant. Post-hoc analysis was performed using the Tukey’s HSD test.
A proportional hazards model was used to identify predictors of
post-operative complications.
Results
Group characteristics are given in Table 1, demonstrating similar-
ity among the three groups based on matching criteria. Table 2
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lists the tumour histologies for the three study groups. Differences
in the distribution of tumour types across treatment groups
reflects the availability (or absence) of effective systemic chemo-
therapeutic options for the various tumour types. Both the pre-
HAT and pre-operative chemotherapy groups had exposure to
one or more systemic chemotherapy regimens before hepatic
resection, detailed in Table 3.
The 40 pre-HAT patients underwent a total of 92 HAT treat-
ments as listed in Table 4. Six patients [three with cholangiocar-
cinoma, two with hepatocellular carcinoma (HCC) and one with
colorectal metastases] underwent sequential therapy with DEB
and yttrium-90 because of a lack of response at initial review, or
loss of response at 6–9 months.
The median time to resection after the last HAT treatment was
6.5 months (range 4–13 months), which is a substantially longer
time to resection when compared with the pre-op chemotherapy
group which was 1 month (range 3 weeks to 3 months), P < 0.01.
At the time of hepatic resection, the senior authors did
not see any difference in peri-hepatic inflammation or adhesions
and the mobilization of all three groups were similar. No
increases in difficulty of hepatic parenchymal transaction were
noted by any operating surgeon. After hepatic resection, the
degree of hepatic inflammation in the non-tumour bearing liver
was graded as none (normal), minimal, moderate or severe by
pathologists based on H&E sections. On review, pathological
examination of the non-tumour bearing liver demonstrated, at
most, moderate inflammation in patients who underwent
pre-HAT.
Table 5 describes the peri-operative characteristics and compli-
cation rates for the study groups. The most commonmajor (grade
Table 1 Group characteristics
Group Pre-HAT Pre-operative chemo No pre-operative Tx P
Number of patients 40 160 640
Median age (range) 60 (27–85) 65 (35–82) 66 (25–81) NS
Median number of lesions (range) 2 (1–5) 2 (1–25) 1 (1–7) NS
Median maximum lesion diameter, cm (range) 3.5 (1.5–9.5) 4 (1.2–9) 4 (1.5–8) NS
Cardiopulmonary disease, n (%) 18 88 (55%) 192 (30%) 0.07
Underlying liver disease, n (%) 8 16 (10%) 32 (5%) 0.06
Major hepatectomy, n (%) 18 90 (56%) 28 (44%) NS
Pre-HAT, pre-operative hepatic arterial therapy; NS, not significant.
Table 2 Disease characteristics of treatment groups
Pre-HAT
n = 40
Pre-op erative
chemo
n = 160
No
pre-opertaive Tx
n = 640
Colorectal
metastases
16 142 (89%) 120 (19%)
Hepatocellular
carcinoma
14 0 132 (20%)
Neuroendocrine 3 2 (1%) 73 (11%)
Cholangiocarcinoma
(intrahepatic)
3 3 (2%) 95 (15%)
Sarcoma 0 1 (1%) 22 (3%)
Breast
metastases
1 2 (1%) 20 (3%)
Melanoma
metastases
0 1 (1%) 14 (2%)
Ovarian
metastases
0 0 18 (3%)
Others 3 9 (6%) 146 (23%)
Pre-HAT, pre-operative hepatic arterial therapy; HCC, hepatocellular
carcinoma.
Table 3 Previous chemotherapy exposures
Pre-HAT
n = 40 pts
Pre-operative chemo
n = 160 pts
FOLFOX, n 7 105
FOLFIRI, n 7 31
Sorafenib, n 3 0
Gemcitabine, n 3 4
Bevacizumab, n 7 55
5-FU, n 6 32
Other, n 18 16
Pre-HAT, pre-operative hepatic arterial therapy.
Note: Many patients had exposure to multiple pre-operative chemo-
therapy regimens.
Table 4 Hepatic arterial therapy treatment characteristics
Y-90 DEB Y-90 + DEB
Number of patients 7 27 6
Number of treatments 18 37 15
Median number of
treatments per patient
(range)
2 (1–2) 2 (1–6) 3 (2–4)
Histology of non-tumour
bearing liver, n (%)
Moderate inflammation, n 5 7 6
Minimal inflammation, n 0 5 0
Normal, n 2 15 0
Y-90, yttrium-90 radioembolization; DEB, drug-eluting bead therapy.
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3) complications in the pre-HAT group were liver dysfunction
and ileus. This was similar to the distribution of complications in
the two comparison groups. The most common liver-specific
complication was liver dysfunction. No specific complication
occurred more often in the pre-HAT group vs. the comparison
groups.
A proportional hazards model for all patients did not demon-
strate any association between increased complications and either
pre-HAT or pre-operative chemotherapy when compared with
patients without pre-operative therapy (P = 0.7).
Discussion
Pre-HAT showed similar morbidity, liver-specific morbidity and
mortality when compared with either patients undergoing pre-
operative chemotherapy or those without pre-operative chemo-
therapy. These results demonstrate that pre-HAT is safe and
should not preclude hepatectomy in well-selected patients.
The lack of operative difficulty in the pre-HAT groups may, in
part, be because of the long interval between HAT therapy and
resection. When comparing the pre-HAT and the pre-operative
chemotherapy groups, the median time to resection after the last
HAT treatment was substantially longer compared with the
median time since last chemotherapy (6.5 vs. 1 month, P < 0.01).
Accordingly, the possibility of greater peri-hepatic inflammation
in the pre-HAT group at earlier resection intervals cannot be
excluded.
On comparison between groups, no statistically significant dif-
ference was found among the three groups with regard to EBL,
complication rate (any complication), occurrence of major com-
plications, frequency of liver specific complications or 90-day
mortality. An increased need for post-operative transfusions was
noted in the pre-operative chemotherapy group (P = 0.04). We
attribute the increased transfusion rate in this group of patients to
the propensity for bone marrow suppression associated with sys-
temic chemotherapy administration.
The similarity between groups in terms of liver-specific com-
plications after resection is somewhat intuitive, given the ability of
HAT to deliver locally effective doses with minimal systemic or
regional toxicity. The finding of minimal to no inflammation in
the non-tumour-bearing liver specimens provides further support
for this concept. As highlighted in our group’s previous report
finding no difference in post-resection morbidity or mortality
after neoadjuvant chemotherapy,10 the duration and timing of
pre-operative therapies are likely related to post-operative
outcomes. Similarly, longer observation times after HAT may
allow for assessment of tumour biology and facilitate a safer
hepatectomy.
Successful downstaging of hepatocellular carcinoma with
yttrium-90 HAT has been described previously.11,12 Our group has
reported on the safety of hepatic resection after yttrium-90 radi-
oembolization for colorectal liver metastases.2 These data expand
upon prior analyses to further demonstrate the safety of hepatic
resection after HAT with either yttrium-90 or drug-eluting beads
in multiple disease histologies. There are limitations to this analy-
sis, related to its retrospective nature, selection bias and the rela-
tively small sample size in the pre-HAT group. However, to our
knowledge, this comprises the largest analysis of patients under-
going HAT followed by resection reported to date.
Judicious selection of candidates for hepatic resection after
HAT is critical to ensure patient safety and tomaximize the poten-
tial for oncological benefit in this challenging patient population.
This requires careful consideration of tumour biology (response
to treatment, disease histology and progression-free interval),
patient comorbidities and functional status, tumour distribution,
hepatic anatomy and estimation of hepatic reserve. While this
study has demonstrated a favourable safety profile in this cohort
of patients undergoing pre-operative hepatic arterial therapy,
further study is warranted to quantify the survival benefit associ-
ated with this novel approach.
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